Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

  • Protagonist Therapeutics PTGX has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ.
  • The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113).
  • FRONTIER 1 is a Phase 2b dose-ranging study to evaluate the safety and efficacy of PN-235 for the treatment of moderate-to-severe plaque psoriasis. 
  • This study is expected to enroll 240 participants.
  • Related: Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate.
  • Protagonist has granted Janssen an exclusive worldwide license to research, develop and commercialize oral IL-23 receptor antagonists.
  • Protagonist is eligible for up to approximately $850 million in development-related milestone payments, in addition to $112.5M in milestones already earned. 
  • Under terms of the collaboration, Janssen will conduct all future clinical studies, including Phase 2 and 3 studies. Janssen will be financially responsible for such studies.
  • Price Action: PTGX shares are up 1.78% at $26.28 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!